Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 4
2007 4
2008 4
2009 3
2010 5
2012 3
2013 2
2014 3
2015 6
2016 5
2017 7
2018 12
2019 14
2020 15
2021 17
2022 14
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Molecular characterization of colorectal cancer related peritoneal metastatic disease.
Lenos KJ, Bach S, Ferreira Moreno L, Ten Hoorn S, Sluiter NR, Bootsma S, Vieira Braga FA, Nijman LE, van den Bosch T, Miedema DM, van Dijk E, Ylstra B, Kulicke R, Davis FP, Stransky N, Smolen GA, Coebergh van den Braak RRJ, IJzermans JNM, Martens JWM, Hallam S, Beggs AD, Kops GJPL, Lansu N, Bastiaenen VP, Klaver CEL, Lecca MC, El Makrini K, Elbers CC, Dings MPG, van Noesel CJM, Kranenburg O, Medema JP, Koster J, Koens L, Punt CJA, Tanis PJ, de Hingh IH, Bijlsma MF, Tuynman JB, Vermeulen L. Lenos KJ, et al. Among authors: bijlsma mf. Nat Commun. 2022 Aug 4;13(1):4443. doi: 10.1038/s41467-022-32198-z. Nat Commun. 2022. PMID: 35927254 Free PMC article.
The molecular biology of peritoneal metastatic disease.
Bootsma S, Bijlsma MF, Vermeulen L. Bootsma S, et al. Among authors: bijlsma mf. EMBO Mol Med. 2023 Mar 8;15(3):e15914. doi: 10.15252/emmm.202215914. Epub 2023 Jan 26. EMBO Mol Med. 2023. PMID: 36700339 Free PMC article. Review.
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. van den Ende T, et al. Among authors: bijlsma mf. Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504550 Clinical Trial.
Genetic and non-genetic risk factors for early-onset pancreatic cancer.
Nodari Y, Gentiluomo M, Mohelnikova-Duchonova B, Kreivenaite E, Milanetto AC, Skieceviciene J, Landi S, Lawlor RT, Petrone MC, Arcidiacono PG, Lovecek M, Gazouli M, Bijlsma MF, Morelli L, Kiudelis V, Tacelli M, Zanette DL, Soucek P, Uzunoglu F, Kaaks R, Izbicki J, Boggi U, Pezzilli R, Mambrini A, Pasquali C, van Laarhoven HW, Katzke V, Cavestro GM, Sperti C, Loos M, Latiano A, Erőss B, Oliverius M, Johnson T, Basso D, Neoptolemos JP, Aoki MN, Greenhalf W, Vodicka P, Archibugi L, Vanella G, Lucchesi M, Talar-Wojnarowska R, Jamroziak K, Saeedi MA, van Eijck CHJ, Kupcinskas J, Hussein T, Puzzono M, Bunduc S, Götz M, Carrara S, Szentesi A, Tavano F, Moz S, Hegyi P, Luchini C, Capurso G, Perri F, Ermini S, Theodoropoulos G, Capretti G, Palmieri O, Ginocchi L, Furbetta N, Canzian F, Campa D. Nodari Y, et al. Among authors: bijlsma mf. Dig Liver Dis. 2023 Oct;55(10):1417-1425. doi: 10.1016/j.dld.2023.02.023. Epub 2023 Mar 25. Dig Liver Dis. 2023. PMID: 36973108 Free article.
The dual role of C/EBPδ in cancer.
Hartl L, Duitman J, Bijlsma MF, Spek CA. Hartl L, et al. Among authors: bijlsma mf. Crit Rev Oncol Hematol. 2023 May;185:103983. doi: 10.1016/j.critrevonc.2023.103983. Epub 2023 Apr 5. Crit Rev Oncol Hematol. 2023. PMID: 37024021 Free article. Review.
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
van den Ende T, Ezdoglian A, Baas LM, Bakker J, Lougheed SM, Harrasser M, Waasdorp C, van Berge Henegouwen MI, Hulshof MCCM, Haj Mohammad N, van Hillegersberg R, Mook S, van der Laken CJ, van Grieken NCT, Derks S, Bijlsma MF, van Laarhoven HWM, de Gruijl TD. van den Ende T, et al. Among authors: bijlsma mf. Oncoimmunology. 2023 Jul 17;12(1):2233403. doi: 10.1080/2162402X.2023.2233403. eCollection 2023. Oncoimmunology. 2023. PMID: 37470057 Free PMC article.
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer.
Campa D, Gentiluomo M, Stein A, Aoki MN, Oliverius M, Vodičková L, Jamroziak K, Theodoropoulos G, Pasquali C, Greenhalf W, Arcidiacono PG, Uzunoglu F, Pezzilli R, Luchini C, Puzzono M, Loos M, Giaccherini M, Katzke V, Mambrini A, Kiudeliene E, Federico KE, Johansen J, Hussein T, Mohelnikova-Duchonova B, van Eijck CHJ, Brenner H, Farinella R, Pérez JS, Lovecek M, Büchler MW, Hlavac V, Izbicki JR, Hackert T, Chammas R, Zerbi A, Lawlor R, Felici A, Götz M, Capurso G, Ginocchi L, Gazouli M, Kupcinskas J, Cavestro GM, Vodicka P, Moz S, Neoptolemos JP, Kunovsky L, Bojesen SE, Carrara S, Gioffreda D, Morkunas E, Abian O, Bunduc S, Basso D, Boggi U, Wlodarczyk B, Szentesi A, Vanella G, Chen I, Bijlsma MF, Kiudelis V, Landi S, Schöttker B, Corradi C, Giese N, Kaaks R, Peduzzi G, Hegyi P, Morelli L, Furbetta N, Soucek P, Latiano A, Talar-Wojnarowska R, Lindgaard SC, Dijk F, Milanetto AC, Tavano F, Cervena K, Erőss B, Testoni SG, Verhagen-Oldenampsen JHE, Małecka-Wojciesko E, Costello E, Salvia R, Maiello E, Ermini S, Sperti C, Holleczek B, Perri F, Skieceviciene J, Archibugi L, Lucchesi M, Rizzato C, Canzian F. Campa D, et al. Among authors: bijlsma mf. Crit Rev Oncol Hematol. 2023 Jun;186:104020. doi: 10.1016/j.critrevonc.2023.104020. Epub 2023 May 8. Crit Rev Oncol Hematol. 2023. PMID: 37164172 Free article. Review.
Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma.
Vallés-Martí A, Mantini G, Manoukian P, Waasdorp C, Sarasqueta AF, de Goeij-de Haas RR, Henneman AA, Piersma SR, Pham TV, Knol JC, Giovannetti E, Bijlsma MF, Jiménez CR. Vallés-Martí A, et al. Among authors: bijlsma mf. Cell Rep. 2023 Jun 27;42(6):112581. doi: 10.1016/j.celrep.2023.112581. Epub 2023 Jun 2. Cell Rep. 2023. PMID: 37269289 Free article.
131 results